Pricing Log in Create free account
Friday 6 November 2026 Export MDGL’s income statement to Excel — free account

Madrigal Pharmaceuticals, Inc.

MDGL Healthcare Biotechnology

Madrigal Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $958.4 million, up 432.1% from fiscal 2024.

Revenue
+50.1%
EPS
+147.3%
Free cash flow
+53.5%
Total debt
+0.45%

Quarter to September 2026, against a year earlier

396.86 3.24 −0.81%
Market cap
$9.3B
P/E
0.0×
Fwd P/E
−68.8×
Dividend yield
—
F-score
n/a
Altman Z
10.48
Beneish M
0.50
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Madrigal Pharmaceuticals, Inc. (MDGL) Book value per share

Alert me on Book value per share

Madrigal Pharmaceuticals, Inc.'s book value per share at the end of fiscal 2025 was 26.9×, down 24.2% from 35.5× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 21.4×. Over the past ten years it has ranged from −286× (fiscal 2015) to 35.5× (fiscal 2024); the current reading is higher than 73% of that period. Madrigal Pharmaceuticals, Inc. ranks 33rd of 611 Biotechnology companies by book value per share.

Book value per share, annual

Embed this chart

Annual newest first

Period Book value per share Change
FY2025 26.9× (24.24%)
FY2024 35.5× 63.50%
FY2023 21.7× 88.30%
FY2022 11.5× (2.88%)
FY2021 11.9× (23.66%)
FY2020 15.5× (42.59%)
FY2019 27.1× (16.06%)
FY2018 32.2× 116.57%
FY2017 14.9× 112.78%
FY2016 7.0× —

Quarterly newest first

Period Book value per share Change
Sep 2026 21.4× 19.29%
Jun 2026 18.0× (4.00%)
Mar 2026 18.7× (30.32%)
Dec 2025 26.9× 22.40%
43 more quarters

Against its own ten years

Low −286× High 35.5×
Ten-year median 15.5×
Current reading's percentile 73

Book value per share against peers

Company Book value per share
KRYS Krystal Biotech, Inc. compare 48.5×
MDGL Madrigal Pharmaceuticals, Inc. 21.4×
PTGX Protagonist Therapeutics, Inc. compare 12.8×
SYRE Spyre Therapeutics, Inc. compare 11.9×
TWST Twist Bioscience Corporation compare 7.1×
TGTX TG Therapeutics, Inc. compare 4.3×
CYTK Cytokinetics, Incorporated compare 0.0×
CAI Caris Life Sciences,�Inc. compare 0.0×
IBRX ImmunityBio, Inc. compare −1.0×

What Book value per share is

BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.

(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))

The full definition of Book value per share →

More on MDGL